Similarly, combining Dasatinib with mTOR inhibitor was more effective than Dasatinib alone in a preclinical model of Ph-like ALL harboring ABL1 or ABL2 rearrangements [88]. Here, ABL1 is linked to acute lymphoblastic leukemia.